K

Kyungdong Pharm
KOSDAQ:011040

Watchlist Manager
Kyungdong Pharm
KOSDAQ:011040
Watchlist
Price: 5 700 KRW -1.21% Market Closed
Market Cap: 153.9B KRW

Relative Value

The Relative Value of one Kyungdong Pharm stock under the Base Case scenario is 6 414.1 KRW. Compared to the current market price of 5 700 KRW, Kyungdong Pharm is Undervalued by 11%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
6 414.1 KRW
Undervaluation 11%
Relative Value
Price
K
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
90
vs Industry
74
Median 3Y
0.9
Median 5Y
1.1
Industry
2.7
vs History
73
vs Industry
18
Median 3Y
19.3
Median 5Y
22.3
Industry
21.6
vs History
53
vs Industry
Median 3Y
-13.8
Median 5Y
7.8
Industry
16.9
vs History
vs Industry
1
Median 3Y
-9.3
Median 5Y
-9.3
Industry
22.9
vs History
92
vs Industry
68
Median 3Y
0.8
Median 5Y
0.8
Industry
2.3
vs History
84
vs Industry
74
Median 3Y
0.9
Median 5Y
1
Industry
3
vs History
93
vs Industry
76
Median 3Y
1.5
Median 5Y
1.8
Industry
5.6
vs History
23
vs Industry
2
Median 3Y
12.9
Median 5Y
9.1
Industry
13.4
vs History
23
vs Industry
Median 3Y
-6.3
Median 5Y
12.6
Industry
16.7
vs History
53
vs Industry
Median 3Y
-14.7
Median 5Y
8
Industry
16.1
vs History
31
vs Industry
Median 3Y
-7.7
Median 5Y
-7.7
Industry
18.9
vs History
92
vs Industry
70
Median 3Y
0.7
Median 5Y
0.7
Industry
2

Multiples Across Competitors

Competitors Multiples
Kyungdong Pharm Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Kyungdong Pharm
KOSDAQ:011040
153.7B KRW 0.8 18.6 14 21.7
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.2 55.5 37.2 39.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
504.6B USD 5.5 20.1 16.4 21.3
CH
Roche Holding AG
SIX:ROG
270.7B CHF 4.4 28.7 12.2 14.3
UK
AstraZeneca PLC
LSE:AZN
217.2B GBP 5 31.1 109.3 159.9
CH
Novartis AG
SIX:NOVN
218B CHF 4.9 19 12 15.5
US
Merck & Co Inc
NYSE:MRK
271.6B USD 4.2 14.3 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.5 11.5 13.3
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.7B USD 2.3 14.6 7.5 10.2
P/E Multiple
Earnings Growth PEG
KR
K
Kyungdong Pharm
KOSDAQ:011040
Average P/E: 24.3
18.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.1
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.1
37%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.3
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
16.5
3%
5.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
K
Kyungdong Pharm
KOSDAQ:011040
Average EV/EBITDA: 401.4
14
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.2
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.4
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
109.3
10%
10.9
CH
Novartis AG
SIX:NOVN
12
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
1%
11.5
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
K
Kyungdong Pharm
KOSDAQ:011040
Average EV/EBIT: 1 714.5
21.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.9
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.3
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.3
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.9
23%
7
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5